Resolution of Pudendal Neuralgia in Chronic Pelvic Pain Using a Novel Biologic Therapy
Unknown statusNCT06425575
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This goal of this study is to determine whether a novel biologic, i.e., an "amniotic suspension allograft" (ASA) will reduce pain and improve quality of life (QoL) in women stricken with chronic pelvic pain (CPP). The main questions it aims to answer are: * Weather pain in the genitalia is reduced with treatment * Weather bladder or urination pain is reduced with treatment * Weather any adverse events occur following treatment Patient responses to pain and QoL will be collected before and 6-12 months after treatment.
Study details
- Official title
- Resolution of Pudendal Neuralgia in Chronic Pelvic Pain Using a Novel Biologic Therapy
- Conditions
- Interventions
- Biological: Amniotic suspension allograft
- Sponsor
- Thomas Jefferson University
- Collaborators
- The Cooper Health System
- Start date
- 2019-04-01
- Primary completion
- 2023-10-31
- Sex
- Female
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: All patients 18 years of age or older who present with chronic pelvic pain - Exclusion Criteria: 1. Under 18 years of age 2. Malignancy defined as terminal -
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06425575